Moreover, we further investigated the role of CD93 in the overall prognosis of glioma patients interconnected with certain major clinical variables such as sex, age, WHO grades, and MGMT promoter methylation status (Fig. 3a, b). This evidence concerns the gene CD93 and central nervous system cancer.